Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

Prevalence of Brain Metastases and Impact on Survival in Metastatic Non-small Cell Lung Cancer by Line of Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06557967

Enrollment

22517

Registered

2024-08-16

Start date

2024-03-01

Completion date

2024-09-30

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain and Central Nervous System Cancer, Lung Cancer, Metastatic Cancer, Non-small Cell Lung Cancer

Keywords

Real World Evidence, NSCLC, Brain metastases

Brief summary

This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.

Detailed description

This retrospective cohort database study will generate real-world evidence describing prevalence of brain metastases at metastatic diagnosis and by line of therapy, patient characteristics, treatment patterns, and clinical outcomes in metastatic non-small cell lung cancer (mNSCLC) patients

Interventions

OTHERNo drug

This is a non-interventional study and no study drug will be provided.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC 2. Age 18+ years at the time of diagnosis of mNSCLC Additional inclusion criteria for 1st Line of Therapy cohort: 3. Treated with systemic anti-cancer therapy in 1L setting Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts: 4. Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting

Exclusion criteria

1. Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period 2. Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS) of (AGA+/-) mNSCLC Participant With And Without Brain Metastases by Line of Therapy	From baseline to end of follow-up or death, whichever comes first, up to approximately 40 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026